Institut Català de la Salut
[Carballo-Carbajal I, Laguna A, Romero-Giménez J, Cuadros T, Bové J, Martinez-Vicente M, Parent A, Gonzalez-Sepulveda M, Peñuelas N, Torra A, Rodríguez-Galván B] Grup de recerca en Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca, Barcelona, Spain. [Vila M] Grup de recerca en Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
Vall d'Hebron Barcelona Hospital Campus
2019-03-29T13:57:59Z
2019-03-29T13:57:59Z
2019-03-07
Brain tyrosinase; Neuromelanin production; Parkinson’s
Tirosinasa cerebral; Producció de neuromelanina; Parkinson
Tirosinasa cerebral; Producción de neuromelanina; Parkinson
In Parkinson's disease (PD) there is a selective degeneration of neuromelanin-containing neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin accumulates with age, the latter being the main risk factor for PD. The contribution of neuromelanin to PD pathogenesis remains unknown because, unlike humans, common laboratory animals lack neuromelanin. Synthesis of peripheral melanins is mediated by tyrosinase, an enzyme also present at low levels in the brain. Here we report that overexpression of human tyrosinase in rat substantia nigra results in age-dependent production of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in elderly humans. In these animals, intracellular neuromelanin accumulation above a specific threshold is associated to an age-dependent PD phenotype, including hypokinesia, Lewy body-like formation and nigrostriatal neurodegeneration. Enhancing lysosomal proteostasis reduces intracellular neuromelanin and prevents neurodegeneration in tyrosinase-overexpressing animals. Our results suggest that intracellular neuromelanin levels may set the threshold for the initiation of PD.
Article
Published version
English
Parkinson, Malaltia de; Aminoàcids - Metabolisme; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosine::Melanins; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosine; Other subheadings::Other subheadings::Other subheadings::/metabolism; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::aminoácidos::aminoácidos cíclicos::aminoácidos aromáticos::tirosina::melaninas; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::aminoácidos::aminoácidos cíclicos::aminoácidos aromáticos::tirosina; Otros calificadores::Otros calificadores::Otros calificadores::/metabolismo
Nature Research
Nature Communications;(10)1
https://www.nature.com/articles/s41467-019-08858-y
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]